Glp1

GLP-1 boom in India, China, Brazil can create $22 bn market: JP Morgan

The addressable ​market could grow at an annual rate of 15% through 2035, JP Morgan ‌analysts led by Yang Huang said in a note on Friday, given the countries' large diabetes and obesity burdens

L'Oreal CEO says rise of weight-loss drugs impacting skincare consumption

L'Oreal is testing products on users of weight-loss drugs, as beauty companies explore treatments for skin changes associated with rapid weight loss

CDMO players bet on complex products such as biologics, peptides for growth

Next phase of growth hinges on biologics, peptides, and drug-device combinations, say industry executives

Semaglutide mkt settles into steady growth six months after patent expiry

Generic brands now account for about 74% of monthly units as lower-priced products expand access, while doctors say the initial rush around the drug is cooling

Egg bites, Burger bowls: McDonald's tests protein-rich menu for GLP-1 users

The fast-food giant is testing chicken and burger bowls, snack wraps and egg bites as some consumers on GLP-1 drugs seek smaller portions and more protein

Mounjaro sales soar 502% as India's GLP-1 drug market expands rapidly

Mounjaro has overtaken other GLP-1 medicines to become India's top-selling brand, as demand for newer diabetes and weight-loss treatments rises

The GLP-1 diet: How weight-loss drugs are changing packaged food business

Weight-loss drugs are changing what consumers buy, putting protein, fibre, smaller portions and nutrient density at the centre of the next packaged-food opportunity

Facelift: South Korean beauty firm targets 'Ozempic face' using human fat

South Korea's L&C Bio plans an injectable skin booster from donated human fat to restore facial volume, targeting cosmetic concerns linked to GLP-1 weight-loss drugs

Novo Nordisk's Wegovy gets CDSCO nod for treatment of fatty liver in India

Novo Nordisk India on Friday said it has received approval from the Central Drugs Standard Control Organisation for indication of its Wegovy injection for the treatment of fatty liver disease in India. The Central Drugs Standard Control Organisation (CDSCO) has approved a new indication for Wegovy (semaglutide injection 2.4 mg), Novo Nordisk India said in a statement. It makes Wegovy the first and only GLP-1 RA to be approved both globally and in India for the treatment of noncirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis along with a reduced calorie diet and increased physical activity, it added. MASH is a liver disease that develops due to excess fat buildup in the liver, causing chronic inflammation and liver damage. Novo Nordisk India MD Vikrant Shrotriya said the burden of MASH continues to rise in India, but treatment options are still severely limited. People with MASH face a higher risk of serious liver .

Explained: Why Nestle is tweaking flavours for people taking GLP-1 drugs

Nestle's chefs are working with people taking GLP-1 drugs to develop new flavour combinations, including potentially using more spices and pepper to compensate for dulled taste perception

Nestle to remove artificial food colourings from all products by end-2026

The world's largest food company said the move extends its clean-label strategy globally as consumers increasingly seek simpler and healthier food ingredients

GLP-1 rush exposes capacity crunch at India's drug manufacturing firms

Demand for GLP-1 drugs such as semaglutide is exposing capacity gaps across peptide APIs, sterile fill-finish facilities, injector devices and glass cartridges

Piramal Pharma to stay away from generic GLP-1 race amid global rush

Piramal Pharma is avoiding the crowded GLP-1 peptide market, focusing instead on niche therapies and specialised manufacturing to drive CDMO growth in FY27

Ozempic-style drugs tied to slower cancer spread in major new study

New findings to be presented at ASCO 2026 suggest GLP-1 medicines may help reduce cancer progression, although experts say more trials are still needed

CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs

CDSCO has directed states and UTs to curb surrogate advertising of GLP-1 obesity drugs amid rising sales and aggressive awareness campaigns

Generic GLP-1 sales increase, but innovators retain market share

Over 25 versions of weight-loss drugs currently available in the market

Biocon eyes in-licensing opportunities to expand biosimilars portfolio

Biocon is scouting for biosimilar in-licensing opportunities while banking on multiple FY27 product launches to drive growth, margins, and market expansion

DRL-Nestle JV launches Celevida product line for GLP-1 therapy patients

Dr Reddy's-Nestle Health Science JV launched Celevida GLP+ to support nutrition and muscle health among patients on GLP-1 and GIP therapies

Canada approves DRL's Ozempic generic after months of regulatory logjam

DRL is the first company to receive market authorisation for a generic semaglutide injection in Canada. It is the first generic semaglutide to be approved in a G7 country

How Chinese oral GLP-1 drugs may reshape India's obesity drug market

With cheaper GLP-1 pills entering India, access could improve significantly, but experts warn that affordability must be balanced with strong regulation and patient safety